Clinical data
ATC code N07XX03 (WHO)
CAS Number 135354-02-8 YesY
PubChem (CID) 128919
ChemSpider 114237 N
KEGG D06327 YesY
Chemical and physical data
Formula C24H22F3N
Molar mass 381.433 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Xaliproden (codenamed SR57746) is a drug which acts as a 5HT1A agonist.[1] It has neurotrophic and neuroprotective effects in vitro,[2][3] and has been proposed for use in the treatment of several neurodegenerative conditions including amyotrophic lateral sclerosis (ALS)[4] and Alzheimer's disease.[5]

Development of xaliproden for these two indications was discontinued in 2007 following analysis of Phase III data. While the drug did show an effect on hippocampal volume (suggesting perhaps a slowing of cell loss), there was insufficient evidence for efficacy in counteracting Alzheimer's related cognitive decline. Similarly while there were some indicators of efficacy in ALS, including a small but clinically noteworthy effect on some functional parameters, the overall benefit did not reach statistical significance when results across several Phase III trials were averaged. Xaliproden remains under investigation for treatment of chemotherapy-induced peripheral neuropathy.[6][7]


  1. Appert-Collin, A; Duong, FH; Passilly Degrace, P; Warter, JM; Poindron, P; Gies, JP (2005). "MAPK activation via 5-hydroxytryptamine 1A receptor is involved in the neuroprotective effects of xaliproden". International Journal of Immunopathology and Pharmacology. 18 (1): 21–31. PMID 15698508.
  2. Labie, C; Lafon, C; Marmouget, C; Saubusse, P; Fournier, J; Keane, PE; Le Fur, G; Soubrié, P (1999). "Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex". British Journal of Pharmacology. 127 (1): 139–44. doi:10.1038/sj.bjp.0702545. PMC 1566010Freely accessible. PMID 10369466.
  3. Duong, FH; Warter, JM; Poindron, P; Passilly, P (1999). "Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons". British Journal of Pharmacology. 128 (7): 1385–92. doi:10.1038/sj.bjp.0702910. PMC 1571767Freely accessible. PMID 10602316.
  4. Meininger, V; Bensimon, G; Bradley, WR; Brooks, B; Douillet, P; Eisen, AA; Lacomblez, L; Leigh, PN; Robberecht, W (2004). "Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials". Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. 5 (2): 107–17. doi:10.1080/14660820410019602. PMID 15204012.
  5. Lemaire L, Fournier J, Ponthus C, Le Fur Y, Confort-Gouny S, Vion-Dury J, Keane P, Cozzone P (2002). "Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats". Invest Radiol. 37 (6): 321–7. doi:10.1097/00004424-200206000-00003. PMID 12021588.
  6. Susman, E (2006). "Xaliproden lessens oxaliplatin-mediated neuropathy". The lancet Oncology. 7 (4): 288. doi:10.1016/S1470-2045(06)70639-8. PMID 16598880.
  7. Wolf, S; Barton, D; Kottschade, L; Grothey, A; Loprinzi, C (2008). "Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies". European Journal of Cancer. 44 (11): 1507–15. doi:10.1016/j.ejca.2008.04.018. PMID 18571399.

This article is issued from Wikipedia - version of the 6/7/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.